Sera Prognostics (SERA)
NASDAQ:SERA
Want to see SERA full AI Analyst Report?
SERA Stock Chart & Stats
$2.30
$0.42(5.34%)
At close: 4:00 PM EST
$2.30
$0.42(5.34%)
Day’s Range― - ―
52-Week Range$1.37 - $4.09
Previous CloseN/A
Volume57.63K
Average Volume (3M)40.22K
Market Cap
$74.40M
Enterprise Value$70.19M
Total Cash (Recent Filing)$39.20M
Total Debt (Recent Filing)$2.34M
Price to Earnings (P/E)―
Beta1.20
Next Earnings
May 06, 2026EPS Estimate
-0.17Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.68
Shares Outstanding38,190,968
10 Day Avg. Volume55,279
30 Day Avg. Volume40,220
Financial Highlights & Ratios
PEG Ratio0.14
Price to Book (P/B)1.86
Price to Sales (P/S)1735.84
P/FCF Ratio-5.34
Enterprise Value/Market Cap0.94
Enterprise Value/Revenue866.59
Enterprise Value/Gross Profit-845.71
Enterprise Value/Ebitda-1.97
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.7
Revenue Forecast (FY)$333.33K
Bulls Say, Bears Say
Bulls Say
Clinical ValidationFormal publication of the PRIME study in a peer-reviewed medical journal validates clinical evidence for the PreTRM test and strengthens commercial discussions with payers and providers.
Payer EngagementBroader payer engagement and targeted partner programs across Medicaid and commercial plans can increase access and coverage for the PreTRM test, supporting higher test utilization.
Valuation OpportunityMarket valuation below reported cash presents an attractive risk/reward profile that may draw investor interest if commercial milestones progress.
Bears Say
Catalyst ScarcityAn uneventful corporate update with few new catalysts could limit stock momentum and reduce investor interest.
Commercial Execution RiskLimited sales resources and a small commercial team increase the risk of constrained execution and slower customer base expansion.
Product Concentration And Pipeline RiskDependence on a single commercial test and an unproven pipeline beyond the initial offering raise revenue concentration and long-term growth concerns.
Sera Prognostics News
SERA FAQ
What was Sera Prognostics’s price range in the past 12 months?
Sera Prognostics lowest stock price was $1.37 and its highest was $4.09 in the past 12 months.
What is Sera Prognostics’s market cap?
Sera Prognostics’s market cap is $74.40M.
When is Sera Prognostics’s upcoming earnings report date?
Sera Prognostics’s upcoming earnings report date is May 06, 2026 which is today.
How were Sera Prognostics’s earnings last quarter?
Currently, no data Available
Is Sera Prognostics overvalued?
According to Wall Street analysts Sera Prognostics’s price is currently Overvalued.
Does Sera Prognostics pay dividends?
Sera Prognostics does not currently pay dividends.
What is Sera Prognostics’s EPS estimate?
Sera Prognostics’s EPS estimate is -0.17.
How many shares outstanding does Sera Prognostics have?
Sera Prognostics has 38,190,968 shares outstanding.
What happened to Sera Prognostics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Sera Prognostics?
Currently, no hedge funds are holding shares in SERA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sera Prognostics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Neutral
SERA Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $96.1K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-58.89%
12-Months-Change
Fundamentals
Return on Equity
-47.69%
Trailing 12-Months
Asset Growth
36.87%
Trailing 12-Months
Company Description
Sera Prognostics
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.
SERA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed strong clinical and strategic progress anchored by PRIME publication (demonstrating large reductions in extreme preterm birth and NICU use), expanded state/payer engagement, leadership hires, and a healthy cash runway through 2028. However, commercial revenue remains extremely modest and volatile (Q4 revenue down ~58%), the company is still unprofitable, and broader payer coverage and real-world adoption are required to convert clinical success into meaningful revenue. On balance, the material clinical evidence, growing partner programs, and multi-year cash runway materially de-risk near-term funding and enable commercialization efforts, outweighing the current low revenue base and execution risks.View all SERA earnings summariesSERA Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Ownership Overview
7.75% Insiders
3.72% Mutual Funds
7.55% Other Institutional Investors
77.63% Public Companies and
Individual Investors